Overview
Plain-language guide
Designed for research into Type 1 diabetes glycemic-control research. It remains investigational for these uses.
It copies two gut-hormone signals that help the body respond to food, regulate blood sugar and communicate fullness to the brain.
Clinical mechanism
Activates GLP-1 and GIP receptors in metabolic research.
Applications
Human evidence
Human trial evidence varies by indication and phase. Trial progression alone does not establish benefit, approval or long-term safety.
Human trials · see profilePreclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Regulatory status
Investigational. Regulatory status is product- and jurisdiction-specific. Confirm the exact product and indication against the current label.
Safety
Uncertain or Concerning
- Human safety data are incomplete
- Product identity, sterility and dose consistency may be unknown
Interactions
Combination data are sparse. Absence of documented interaction evidence is not evidence of compatibility.
Treatment pattern
Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Roche · Phase 2 (April 2026 snapshot). Development programs and ownership can change; confirm current sponsor disclosures.
Sources
2026-04-23: Dated sponsor pipeline lists acmopatide (CT-868) in Phase 2 for type 1 diabetes glycemic control.
- 01Roche: April 2026 development pipeline ↗
Sponsor · 2026-04-23
Gaps and unverified claims
- Long-term outcomes and real-world safety are not yet established.
- Current phase and catalysts require primary-source confirmation.
Last reviewed
September 23, 2026 (listed facts only) · Primary-source check needed